Fragile X syndrome clinical trials: exploring parental decision-making.
Parents enroll in FXS drug trials when outcome measures match the child’s most bothersome symptoms and the logistics are manageable.
01Research in Context
What this study did
Bergmann et al. (2019) talked to parents of kids with Fragile X syndrome. They asked why some parents say yes to drug trials and others walk away.
The team used open-ended questions. Parents told their stories in their own words.
What they found
Enrollers wanted the exact symptom fixed that bothered them most. If the study measured that symptom, they signed.
Decliners feared side effects or long drives. Busy schedules and worry kept them out.
How this fits with other research
Protic et al. (2022) later wrote that early combo care—drugs plus behavior plans—is now best practice for FXS. Their review folds in this parent view: match the target symptom or families won’t join.
Acar et al. (2021) looked at three cultures and found moms do most of the work. That wider lens shows the FXS finding is part of a bigger picture: moms weigh risk, time, and child need across conditions.
Chou et al. (2010) watched moms of kids with FXS answer frustration in real time. Together the two studies show moms act on child signals—both in daily play and when picking trials.
Why it matters
When you recruit for FXS or any drug study, show parents the exact item on the outcome list that matches their top worry. Offer rides, short visits, and clear side-effect data. This simple fit can turn a no into a yes and keep enrollment on track.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Open the consent form, circle the one outcome that matches the parent’s top concern, and read it aloud together.
02At a glance
03Original abstract
BACKGROUND: The objective of this research was to understand parental proxy decision-making for drug trial participation for children with Fragile X syndrome (FXS). Specifically, we aimed to capture preferences, motivations, influencing factors and barriers related to trial involvement among trial joiners and decliners and describe ease of trial decision-making and decisional regret. METHODS: Interviews were conducted with parents from two groups: those who chose to enrol their child with FXS in a trial (N = 16; Joiners) and those who declined trial participation (N = 15; Decliners). Data were coded and interpreted through inductive content analysis. RESULTS: Prominent decisional factors included attitudes about medicating FXS symptoms, potential for direct benefit (primarily evaluated through the degree of match between target outcomes and child symptomatology and drug mechanism), logistical convenience and perceived risks of side effects. The ultimate motivation for participation was potential for direct benefit. None of the parents reported decisional regret, and ease of decision-making ranged from easy to difficult for our participants. CONCLUSIONS: Therapeutic optimism was high among those who elected participation. Parents may benefit from an explanation of the rationale behind chosen outcome variables and may be more interested in trials that target or measure as an exploratory outcome the symptoms they find most concerning. Our findings reinforce the need for future trials to reduce participant inconvenience. Our results contrast with what has previously been observed in parents of children with life-threatening conditions; parents of children with FXS may be more trial risk averse and find trial decisions to be harder. Parents of children with FXS considering trials may benefit from a decisional intervention aimed at deliberating motivations and barriers.
Journal of intellectual disability research : JIDR, 2019 · doi:10.1016/j.cct.2010.08.007